Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: A post-hoc analysis of patients taking 1-3 mg/24 h for up to 5 years

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 1, 2013, Pages 15-25

  Dohin, Elisabeth ^a   Högl, Birgit ^b   Ferini Strambi, Luigi ^c   Schollmayer, Erwin ^a   Fichtner, Andreas ^a   Bauer, Lars ^a   García Borreguero, Diego ^d  

^a UCB PHARMA   (Belgium)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d SLEEP RESEARCH INSTITUTE   (Spain)

Author keywords

Dopamine receptor agonists; Restless legs syndrome; Transdermal patch

Indexed keywords

ROTIGOTINE;

ADULT; AGED; APPLICATION SITE REACTION; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; DEPRESSION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PROSPECTIVE STUDY; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SLEEP DISORDER; TREATMENT DURATION; VARICOSIS; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; TETRAHYDRONAPHTHALENES; THIOPHENES; TRANSDERMAL PATCH; TREATMENT OUTCOME;

EID: 84871558778     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.758251     Document Type: Article

References (27)

1. Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol 2010;6:337-46
2. International Restless Legs Syndrome Study Group. Revised IRLSSG diagnostic criteria for RLS. Available from: http://irlssg.org/diagnostic- criteria/[Last accessed 28 November, 2012]
3. Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med 2000;1:11-19
4. Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008;23:2267-302
5. Garcia-Borreguero D, Stillman P, Benes H, et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol 2011;11:28
6. Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol 2012;19(11):1385-96
7. Scheller D, Ullmer C, Berkels R, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2009;379:73-86
8. Elshoff JP, Braun M, Andreas JO, et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012;34:966-78
9. Neupro (rotigotine transdermal patch). European summary of product characteristics. UCB Pharma, Co; Clare, Ireland: 2012
10. Neupro (rotigotine transdermal system). US prescribing information. UCB Pharma; Smyrna, GA: 2012
11. Oertel WH, Benes H, Garcia-Borreguero D, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008;9:228-39 (Pubitemid 351391727)
12. Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604
13. Hening WA, Allen RP, Ondo WG, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord 2010;25:1675-83
14. Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med 2010;11:848-56
15. Oertel W, Trenkwalder C, Benes H, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 2011;10:710-20
16. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19 (Pubitemid 36527231)
17. National Institute of Mental Health. 028 CGI. Clinical Global Impressions. ECDEU assessment manual for psychopharmacology. U.S. Department of Health, Education, and Welfare; Rockville, MD; 1976. p. 217-22
18. Garcia-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007;8:520-30 (Pubitemid 46972001)
19. Garcia-Borreguero D, Williams AM. Dopaminergic augmentation of restless legs syndrome. Sleep Med Rev 2010;14:339-46
20. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-32 (Pubitemid 36527232)
21. Kohnen R, Oertel WH, Stiasny-Kolster K, et al. Severity rating of restless legs syndrome: validation of the RLS-6 scales. Sleep 2004;27:304
22. Kohnen R, Benes H, Heinrich CR, et al. Development of the disease-specific Restless Legs Syndrome Quality of Life (RLS-QoL) questionnaire. Mov Disord 2002;17:S232-S
23. Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotinetransdermal patch in early Parkinson's disease: a randomized, double-blind, controlled studyversus placebo and ropinirole. Mov Disord 2007;22:2398-404 (Pubitemid 351155987)
24. Watts RL, Jankovic J, Waters C, et al. Randomized, blind,controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-6 (Pubitemid 46148338)
25. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine inadvanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513-20 (Pubitemid 46734759)
26. LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotinetransdermal system: PREFER Study. Neurology 2007;68:1262-7 (Pubitemid 46625971)
27. Trenkwalder C, Benes H, PoeweW, et al. Efficacy of rotigotine for treatment of moderate-to-severe RLS: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604